Work

First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers.

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.7530

Authors: Mark G. Kris, Tony Mok, Sai-Hong Ignatius Ou, Renato Martins, Dong-Wan Kim, Zelanna Goldberg, Hui Zhang, Ian Taylor, Stephen P. Letrent, Pasi Antero Janne

Institutions: Memorial Sloan Kettering Cancer Center, Chinese University of Hong Kong, UC Irvine Chao Family Comprehensive Cancer Center, Seattle Cancer Care Alliance, University of Washington, Seoul National University, Seoul National University Hospital, Pfizer (United States), Pfizer (China), Dana-Farber Cancer Institute

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2604095005

Cites:

Cited by: 41

Related to: 10